ESR1 and breast cancer: Collectively, these preclinical studies suggest that dual pathway targeting by vepdegestrant and CDK4/6 or PI3K/mTOR signaling could result in better therapeutic outcomes for patients with advanced ER+/HER2− breast cancer [121].